Beta Portal @ linkeddatafragments.org

Matches in Stad Gent for { <https://stad.gent/id/news/831211> ?p ?o ?g. }

• 831211 type NewsArticle news.
• 831211 isDefinedBy 831211 news.
• 831211 subject "https://stad.gent/en/invest-ghent" news.
• 831211 description "In a world where chemical pesticides are increasingly scrutinised, Ghent-based Biotalys is developing a biological alternative. " news.
• 831211 identifier "831211" news.
• 831211 image CVE-2024-01-18-BioTalys-0300b.jpg news.
• 831211 inLanguage "en" news.
• 831211 isPartOf 615 news.
• 831211 isPartOf 629 news.
• 831211 keywords "6799" news.
• 831211 url camels-crops-ghent-based-biotalys-pioneer-biological-plant-protection news.
• 831211 dateModified "2025-10-20T18:02:04+00:00" news.
• 831211 datePublished "2025-10-20T18:02:04+00:00" news.
• 831211 headline "From camels to crops: Ghent-based Biotalys is a pioneer in biological plant protection" news.
• 831211 articleBody " <div class="paragraph paragraph--type--text paragraph--view-mode--full"> <p><span lang="EN-GB">What began as a technology rooted in the pharmaceutical industry is now evolving into a smart solution for crop protection. Their products not only make agriculture more sustainable and resilient, but they also offer a safer approach for farmers, consumers, and nature alike.</span></p><p><span lang="EN-GB">Over the past decade, Biotalys has been breaking new ground in </span><a href="https://stad.gent/en/invest-ghent/future-tech/biotech"><span lang="EN-GB">agrotech</span></a><span lang="EN-GB">. That pioneering work may soon be rewarded with the approval of their first product, Evoca, by the U.S. Environmental Protection Agency (EPA). Once granted, this recognition will mark the technology as officially safe by government standards.</span></p><p><span lang="EN-GB">This pivotal moment is the perfect opportunity to speak with Dr Carlo Boutton, Chief Scientific Officer. “We’re on the verge of a major breakthrough,” he says.</span></p> </div> <div class="paragraph paragraph--type--container paragraph--view-mode--full w10-o1"> <ul class="grid-2"> <li> <div class="paragraph paragraph--type--image paragraph--view-mode--default"> <div class="image-gallery--wrapper single"> <div class="image-gallery js-lightbox"> <a href="https://stad.gent/sites/default/files/styles/gallery_full/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=TthcK4oE" class="gallery-link" aria-describedby="image-gallery__open-gallery" > <figure> <picture> <source srcset="/sites/default/files/styles/wide_l/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=Z8HMREtf 1x, /sites/default/files/styles/wide_l_x2/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=PGRe0rIn 2x" media="(min-width: 1680px)" type="image/webp" width="655" height="982"/> <source srcset="/sites/default/files/styles/wide_l/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=Z8HMREtf 1x, /sites/default/files/styles/wide_l_x2/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=PGRe0rIn 2x" media="all and (min-width: 960px) and (max-width: 1679.9px)" type="image/webp" width="655" height="982"/> <source srcset="/sites/default/files/styles/wide_xxl/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=jfPsJfg- 1x, /sites/default/files/styles/wide_xxl_x2/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=dhvwVzu7 2x" media="all and (min-width: 768px) and (max-width: 959.9px)" type="image/webp" width="920" height="1379"/> <source srcset="/sites/default/files/styles/wide_xl/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=4Wl3XcIs 1x, /sites/default/files/styles/wide_xl_x2/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=dxrdaLyL 2x" media="all and (min-width: 576px) and (max-width: 767.9px)" type="image/webp" width="727" height="1090"/> <source srcset="/sites/default/files/styles/wide_m/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=BUCCct6I 1x, /sites/default/files/styles/wide_m_x2/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=JZAnFPgc 2x" media="all and (max-width: 575.9px)" type="image/webp" width="575" height="862"/> <img loading="lazy" width="1840" height="2758" src="/sites/default/files/styles/wide_xxl_x2/public/media/images/CVE-2024-01-18-BioTalys-0563b.jpg.webp?itok=dhvwVzu7" alt="CSO Carlo Boutton" /> </picture> </figure> </a> </div> </div> </div> </li> <li> <div class="quote-wrapper"> <div class="quote"> <blockquote> <div class="content"> <p> Our greatest strength lies in the fact that this technology allows us to develop multiple products. </p> </div> <footer> Dr Carlo Boutton </footer> </blockquote> </div> </div> </li> </ul> </div> <div class="paragraph paragraph--type--text paragraph--view-mode--full"> <h2><span lang="EN-GB"><strong>From VIB spin-off to biotech pioneer</strong></span><span lang="EN-GB"></span></h2><p><span lang="EN-GB">But first, let’s rewind to where it all began. The company was founded in 2013, though the technology it’s built on dates back much further. “Well, Professor Raymond Hamers (VUB) discovered a new type of antibody in the blood of a dromedary back in 1989,” Carlo explains. “A few years later, Ablynx was founded to work with these so-called ‘nanobodies’. Among other things, they brought Cablivi to market, a treatment for TTP, a rare and life-threatening blood disorder. Several other companies followed in their footsteps, also working with these special camelid antibodies. Many of them are based in Ghent, by the way.”</span></p><p><span lang="EN-GB">Some researchers realised that this science could also be applied in agriculture. That insight led to the founding of </span><a href="https://www.biotalys.com/"><span lang="EN-GB">Biotalys </span></a><span lang="EN-GB">in 2013, as a spin-off from the Flemish Institute for Biotechnology (VIB), to develop a technology platform for biological crop protection.</span></p><p><span lang="EN-GB">The concept of a ‘platform’ is central to Biotalys. “Our greatest strength lies in the fact that this technology allows us to develop multiple products. Right now, we’re mainly focused on biofungicides - biological crop protection against fungal diseases - for a wide range of crops like grapes, strawberries, and more. In addition to our first product, Evoca, we’re also working on six other solutions targeting fungi and insect pests.”</span></p><p><span lang="EN-GB">That pioneering work is what truly excites Carlo. “The idea that you get to build something with a team of brilliant scientists, something that’s never been done before. You see the potential applications, but you know there are still many hurdles to overcome. Just imagine if it all works out. The sense of achievement would be enormous. The societal impact alone would be massive.”</span></p> </div> <div class="paragraph paragraph--type--container paragraph--view-mode--full w10-o1"> <ul class="grid-2"> <li> <div class="quote-wrapper"> <div class="quote"> <blockquote> <div class="content"> <p> The idea that you get to build something with a team of brilliant scientists, something that’s never been done before. You see the potential applications, but you know there are still many hurdles to overcome. Just imagine if it all works out. </p> </div> <footer> Dr Carlo Boutton </footer> </blockquote> </div> </div> </li> <li> <div class="paragraph paragraph--type--image paragraph--view-mode--default"> <div class="image-gallery--wrapper single"> <div class="image-gallery js-lightbox"> <a href="https://stad.gent/sites/default/files/styles/gallery_full/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=KF6Dvo9k" class="gallery-link" aria-describedby="image-gallery__open-gallery" > <figure> <picture> <source srcset="/sites/default/files/styles/wide_l/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=QA37KYMM 1x, /sites/default/files/styles/wide_l_x2/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=iR9shg0b 2x" media="(min-width: 1680px)" type="image/webp" width="655" height="982"/> <source srcset="/sites/default/files/styles/wide_l/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=QA37KYMM 1x, /sites/default/files/styles/wide_l_x2/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=iR9shg0b 2x" media="all and (min-width: 960px) and (max-width: 1679.9px)" type="image/webp" width="655" height="982"/> <source srcset="/sites/default/files/styles/wide_xxl/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=mZo4Q2xg 1x, /sites/default/files/styles/wide_xxl_x2/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=FK_gs4tO 2x" media="all and (min-width: 768px) and (max-width: 959.9px)" type="image/webp" width="920" height="1379"/> <source srcset="/sites/default/files/styles/wide_xl/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=FbG7rnFV 1x, /sites/default/files/styles/wide_xl_x2/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=x8W7cmDq 2x" media="all and (min-width: 576px) and (max-width: 767.9px)" type="image/webp" width="727" height="1090"/> <source srcset="/sites/default/files/styles/wide_m/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=Wn4t_xV8 1x, /sites/default/files/styles/wide_m_x2/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=APXH1X61 2x" media="all and (max-width: 575.9px)" type="image/webp" width="575" height="862"/> <img loading="lazy" width="1334" height="2000" src="/sites/default/files/styles/wide_xxl_x2/public/media/images/Picture%20Tom%20D_8.jpg.webp?itok=FK_gs4tO" alt="Biotalys 2" /> </picture> </figure> </a> </div> </div> </div> </li> </ul> </div> <div class="paragraph paragraph--type--text paragraph--view-mode--full"> <h2><span lang="EN-GB"><strong>Evoca: The flagship product of the Agrobody platform</strong></span><span lang="EN-GB"></span></h2><p><span lang="EN-GB">This first product is a biofungicide that combats grey mould and powdery mildew,  diseases that wreak havoc on fruit and vegetable crops, often leading to rot. “Our treatment works preventively. Farmers spray their crops in advance to stop infections before they start. If fungal spores land on the plants, they don’t get the chance to develop,” Carlo explains. “We’ve conducted hundreds of field trials across the globe, under a wide range of conditions. We can confidently demonstrate that our biological product performs just as well as chemical alternatives in a typical spray programme.”</span></p><p><span lang="EN-GB">With Evoca, Biotalys offers farmers a fully-fledged alternative. Chemical pesticides are gradually disappearing from the market, not only because they pose health risks but also due to their impact on soil quality. Some of these chemicals harm soil life, leading to degradation and nutrient loss. That creates a vicious cycle, forcing farmers to seek out new land. Evoca also provides a solution to resistance, which is becoming an increasing issue with chemical treatments.</span></p><p><span lang="EN-GB">All these advantages make farmers receptive to Biotalys’ solution, which is no small feat. Agriculture tends to be more conservative than the pharmaceutical sector, where nanobody technology is already well established. And understandably so: farmers often have just one harvest a year and need to protect their income. “But we’re seeing real buy-in from our target groups,” Carlo says. “In fact, we regularly get emails and calls from growers asking when they can start using the product. That’s the ultimate proof.”</span></p><p><span lang="EN-GB">To prepare for commercialisation, Biotalys is now scaling up production of Evoca. “We’re doing that internally, but also in collaboration with the </span><a href="https://www.bbeu.org/"><span lang="EN-GB">Bio Base Europe Pilot Plant</span></a><span lang="EN-GB"> (Ghent) and other industrial partners. We prepare the formulation, then carry out a ‘tech transfer’ to one of these partners. They know exactly what they’re doing, and we work closely together. For distribution, we partner with commercial producers in local markets. Our own focus remains firmly on research and product development, which is reflected in our team: around 50 of our 65 employees are active in R&D. And that’s exactly what this phase requires.”</span></p> </div> <div class="paragraph paragraph--type--container paragraph--view-mode--full w10-o1"> <ul class="grid-2"> <li> <div class="paragraph paragraph--type--image paragraph--view-mode--default"> <div class="image-gallery--wrapper single"> <div class="image-gallery js-lightbox"> <a href="https://stad.gent/sites/default/files/styles/gallery_full/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=a_O0RKsu" class="gallery-link" aria-describedby="image-gallery__open-gallery" > <figure> <picture> <source srcset="/sites/default/files/styles/wide_l/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=4pf0e2Uu 1x, /sites/default/files/styles/wide_l_x2/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=14YXulCd 2x" media="(min-width: 1680px)" type="image/webp" width="655" height="436"/> <source srcset="/sites/default/files/styles/wide_l/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=4pf0e2Uu 1x, /sites/default/files/styles/wide_l_x2/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=14YXulCd 2x" media="all and (min-width: 960px) and (max-width: 1679.9px)" type="image/webp" width="655" height="436"/> <source srcset="/sites/default/files/styles/wide_xxl/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=lu-7B4Ib 1x, /sites/default/files/styles/wide_xxl_x2/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=EWZB-Jx9 2x" media="all and (min-width: 768px) and (max-width: 959.9px)" type="image/webp" width="920" height="612"/> <source srcset="/sites/default/files/styles/wide_xl/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=kB-YUCNT 1x, /sites/default/files/styles/wide_xl_x2/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=9-_4scnN 2x" media="all and (min-width: 576px) and (max-width: 767.9px)" type="image/webp" width="727" height="484"/> <source srcset="/sites/default/files/styles/wide_m/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=3H9TUwoS 1x, /sites/default/files/styles/wide_m_x2/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=Qmp77i3W 2x" media="all and (max-width: 575.9px)" type="image/webp" width="575" height="383"/> <img loading="lazy" width="1840" height="1224" src="/sites/default/files/styles/wide_xxl_x2/public/media/images/20221025-152718-biotalys-IneDehandschutter.jpg.webp?itok=EWZB-Jx9" alt="Evoca" /> </picture> </figure> </a> </div> </div> </div> </li> <li> <div class="quote-wrapper"> <div class="quote"> <blockquote> <div class="content"> <p> We’re not just breaking ground in terms of technology, but also in terms of regulation. Regulatory bodies are used to analysing chemical products. Now we’re presenting something entirely different: a protein-based solution. </p> </div> <footer> Dr Carlo Boutton </footer> </blockquote> </div> </div> </li> </ul> </div> <div class="paragraph paragraph--type--text paragraph--view-mode--full"> <h2><span lang="EN-GB"><strong>New technology demands a new playing field</strong></span><span lang="EN-GB"></span></h2><p><span lang="EN-GB">Developing a new product within this technology platform takes around 8 to 10 years. That may sound like a long time, but it’s not just about the research. The product must also be tested, scaled up, and ultimately approved. And it’s that final step that takes up the most time. “Once we secure that first approval, we hope it will pave the way for other products based on this technology. We understand it takes time. Every piece of evidence, study, etc., needs to be thoroughly reviewed.”</span></p><p><span lang="EN-GB">So how do you even begin such an approval process? “In our case, we approached a European member state, the Netherlands. They have strong expertise in biological crop protection, which means other member states are likely to follow their lead. Over the years, they’ve built up a solid reputation.”</span></p><p><span lang="EN-GB">From there, a wide range of studies is required. You need to prove the product works, based on field trials. You also have to demonstrate that it’s non-toxic, since it’s used on food crops. That means mapping out the entire composition of the product. Who manufactures it? What are the potential deviations? It’s become a pretty comprehensive dossier. The Dutch authorities have now issued a positive recommendation to their European counterparts. The next step is for the European Commission to take the file forward.</span></p><p><span lang="EN-GB">When Carlo speaks with people - especially investors – their first or second question is how far along Evoca is in the approval process. “Yes, you can tell people are watching us closely. And that’s no surprise. We’re not just breaking ground in terms of technology, but also in terms of regulation. Regulatory bodies are used to analysing chemical products. Now we’re presenting something entirely different: a protein-based solution. That’s a major shift, and experts need time to get up to speed. Once we get approval in the U.S., we know interest in our technology will surge. It will also open doors for researchers who come after us. I strongly believe this is the most important milestone we’ll ever have to reach. Not just for now, but for the long term.”</span></p> </div> <div class="paragraph paragraph--type--container paragraph--view-mode--full w10-o1"> <ul class="grid-2"> <li> <div class="quote-wrapper"> <div class="quote"> <blockquote> <div class="content"> <p> I strongly believe this is the most important milestone we’ll ever have to reach. </p> </div> <footer> Dr Carlo Boutton </footer> </blockquote> </div> </div> </li> <li> <div class="paragraph paragraph--type--image paragraph--view-mode--default"> <div class="image-gallery--wrapper single"> <div class="image-gallery js-lightbox"> <a href="https://stad.gent/sites/default/files/styles/gallery_full/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=Ud7YTYmQ" class="gallery-link" aria-describedby="image-gallery__open-gallery" > <figure> <picture> <source srcset="/sites/default/files/styles/wide_l/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=s1J64Mm_ 1x, /sites/default/files/styles/wide_l_x2/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=TZjInIMN 2x" media="(min-width: 1680px)" type="image/webp" width="655" height="437"/> <source srcset="/sites/default/files/styles/wide_l/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=s1J64Mm_ 1x, /sites/default/files/styles/wide_l_x2/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=TZjInIMN 2x" media="all and (min-width: 960px) and (max-width: 1679.9px)" type="image/webp" width="655" height="437"/> <source srcset="/sites/default/files/styles/wide_xxl/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=JdWqjH-Y 1x, /sites/default/files/styles/wide_xxl_x2/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=WLVEjgDT 2x" media="all and (min-width: 768px) and (max-width: 959.9px)" type="image/webp" width="920" height="614"/> <source srcset="/sites/default/files/styles/wide_xl/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=xtv451DH 1x, /sites/default/files/styles/wide_xl_x2/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=_pAF3ngK 2x" media="all and (min-width: 576px) and (max-width: 767.9px)" type="image/webp" width="727" height="485"/> <source srcset="/sites/default/files/styles/wide_m/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=5ONkJouI 1x, /sites/default/files/styles/wide_m_x2/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=3N0RRWXS 2x" media="all and (max-width: 575.9px)" type="image/webp" width="575" height="384"/> <img loading="lazy" width="1840" height="1228" src="/sites/default/files/styles/wide_xxl_x2/public/media/images/CVE-2024-01-18-BioTalys-0358b.jpg.webp?itok=WLVEjgDT" alt="Biotalys 3" /> </picture> </figure> </a> </div> </div> </div> </li> </ul> </div> <div class="paragraph paragraph--type--text paragraph--view-mode--full"> <h2><span lang="EN-GB"><strong>Looking beyond the field</strong></span><span lang="EN-GB"></span></h2><p><span lang="EN-GB">In the not-so-distant future, products from Biotalys’ “Agrobody platform” will be applicable across various niches. “We’re constantly launching new research tracks. That’s the beauty of working with talented scientists,” Carlo explains. “Right now, we’re exploring post-harvest applications in collaboration with Agrofresh in the U.S. How can we extend the shelf life of produce? From our conversations with growers, we’ve learned that even extending the shelf life of strawberries by a single day could have a huge impact on profit margins. That’s something retailers are eagerly waiting for, too. Just imagine how much spoiled fruit and vegetables they could avoid destroying. That’s another area where Biotalys wants to make a difference. We aim to expand our scope across the entire value chain, even if that’s still a vision for the future.”</span></p><p><span lang="EN-GB">Carlo continues, " We’re inevitably moving towards more sustainable agriculture. The way we’re doing things now simply isn’t viable. Do we really need tomatoes at Christmas? Let’s work more in tune with the seasons. I also think current food prices are unsustainable. For us, as ‘wealthy Europeans’, food is incredibly cheap. If we want to be more sustainable, we’ll need to be willing to pay more. I recently saw broccoli in the supermarket for 70 cents. What’s left for the farmer? I don’t even want to think about it. Fortunately, we’re seeing that the demand for sustainable food is no longer just a trend, it’s becoming a societal expectation.”</span></p> </div> <div class="paragraph paragraph--type--call-to-action paragraph--view-mode--full cta-block image-none link"> <div class="cta-block__content"> <div class="feature-block secondary"> <h2>Discover Invest in Ghent</h2> <p>Are you eager to become part of this inspiring biotech ecosystem, just like Biotalys? The team at Invest in Ghent is ready to help you start or scale your business in Ghent through our expert local guidance and introductions, enabling your business to grow even further.</p> <ul class="links"> <li> <a href="https://stad.gent/en/invest-ghent/contact" class="button button-secondary">Contact us</a> </li> <li> <a href="https://www.linkedin.com/showcase/75060038" class="standalone-link">Follow us on LinkedIn</a> </li> </ul> </div> </div> </div> " news.
• 831211 page 831211 news.
• 831211 articleSection "Invest in Ghent" news.